课题基金 / 基金详情

Biology and Treatment of Human Myeloid Cancers

Biology and Treatment of Human Myeloid Cancers
人类骨髓癌的生物学和治疗
批准号：
MC_UU_00029/8
负责人：
Paresh Vyas
金额：
$319.44万
依托单位：
University of Oxford
依托单位国家：
英国
项目类别：
Intramural
财政年份：
2022
资助国家：
英国
项目状态：
未结题
起止时间：
2022 至 --
来源：
https://gtr.ukri.org/projects?ref=MC_UU_00029%2F8
关键词：
BiologyTreatmentHumanMyeloidCancers

项目摘要

项目成果

Paresh Vyas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Blood cancers are the 5th most common cancers. This program studies the biology of the most common aggressive adult leukemia, acute myeloid leukemia and blood disorders related to it. The programme is tracing these cancers from the first events that establish the foundations for these cancers to develop late in life, to the events that lead to fully formed cancers. The programme is also to devlope new treatments that harms the power of the immune sustem to cure these cancers.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
AML-432 突变等位基因（R140 或 R172）在随机、开放性研究中接受 Enasidenib 或常规治疗方案 (CCR) 治疗的晚期、突变复发/难治性急性髓系白血病 (AML) 患者的总生存 (OS)
DOI： 10.1016/s2152-2650(22)01293-9
发表时间： 2022
期刊： Clinical Lymphoma Myeloma and Leukemia
影响因子： 2.7
作者： [DiNardo C]
通讯作者： DiNardo C
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
DOI： 10.1158/2159-8290.cd-22-0332
发表时间： 2022-11-02
期刊： CANCER DISCOVERY
影响因子： 28.2
作者： [Daver, Naval G., Maiti, Abhishek, Kadia, Tapan M., Vyas, Paresh, Majeti, Ravindra, Wei, Andrew H., Garcia-Manero, Guillermo, Craddock, Charles, Sallman, David A., Kantarjian, Hagop M.]
通讯作者： Kantarjian, Hagop M.
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
分化抗体的耐受性和疗效47抗体Magrolimab与阿扎西替丁在先前未经治疗的AML：IB期结果的患者中结合使用。
DOI： 10.1200/jco.22.02604
发表时间： 2023-11-01
期刊： Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子： --
作者： []
通讯作者：
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
DOI： 10.1182/blood.2021014901
发表时间： 2023-01-12
期刊： BLOOD
影响因子： 20.3
作者： [de Botton, Stephane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Joerg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Doehner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, DiNardo, Courtney D.]
通讯作者： DiNardo, Courtney D.
共 6 条
    Identification, characterisation and therapeutic targeting of leukaemic stem/propagating cells in Acute Myeloid Leukaemia
    • 批准号：
      MC_UU_00016/11
    • 项目类别：
      Intramural
    • 资助金额：
      $176.73万
    • 财政年份：
      2017
    • 负责人：
      Paresh Vyas
    • 依托单位：
      University of Oxford
    Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours).
    • 批准号：
      MR/L008963/1
    • 项目类别：
      Research Grant
    • 资助金额：
      $64.11万
    • 财政年份：
      2015
    • 负责人：
      Paresh Vyas
    • 依托单位：
      University of Oxford
    Development ofTherapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells
    • 批准号：
      G1000729/1
    • 项目类别：
      Research Grant
    • 资助金额：
      $253.86万
    • 财政年份：
      2010
    • 负责人：
      Paresh Vyas
    • 依托单位：
      University of Oxford
    海外基金